Lenivia 1,5 mg/ml 2 x 1 ml

Instructions for use

Dosage and treatment schedule:

The recommended dose is 0.05–0.1 mg/kg body weight, once every three months.

Administer according to the dosage table below.

Dogs weighing < 5.0 kg: aseptically withdraw 0.1 ml/kg from a single vial of 0.5 mg and administer subcutaneously. For volumes ≤ 0.5 ml, use a 1.0 or 0.5 ml syringe and measure to an accuracy of 0.1 ml. Discard any remaining contents in the vial.

For dogs weighing 60.1 kg or more, the contents of more than one vial are required. In such cases, draw up the contents of each required vial into the same syringe and administer as a single dose.

Per 1 ml vial:

Active ingredients:

izenivetmab*: 0.5 mg

• 1.0 mg
• 1.5 mg
• 2.0 mg
• 3.0 mg

*Izenivetmab is a caninised monoclonal antibody directed against canine nerve growth factor (NGF), expressed in Chinese hamster ovary (CHO) cells using recombinant techniques.

Excipients:

Qualitative composition of excipients and other constituents

• L-histidine
• Histidine hydrochloride monohydrate
• Trehalose dihydrate
• Disodium EDTA dihydrate
• L-methionine
• Poloxamer 188
• Water for injections
• Clear to slightly opalescent solution, free from visible particles.

Veterinary advice

Dogs:

Common (1 to 10 animals in 100 treated):

• Immediate pain at the injection site

Uncommon (1 to 10 animals in 1,000 treated):

• Ataxia, polydipsia, polyuria

Rare (1 to 10 animals per 10,000 treated animals):

• Lethargy, anorexia

Very rarely (<1 animal/10,000 treated animals, including isolated reports):

• Hypersensitivity reaction (swelling of the head)1, immune-mediated haemolytic anaemia, immune-mediated thrombocytopenia

1In the event of such reactions, appropriate symptomatic treatment should be administered.